Arkansas is currently home to 726 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Little Rock, Jonesboro, Hot Springs and Fayetteville. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue
NCT05268224
Recruiting
Investigation of a tear-based, lab-developed biological test for breast cancer, as a supplemental tool to current screening recommendations for women with dense breast tissue will explore if a tear-based biological test can be used as a support tool in the breast cancer screening protocol for women with dense breast tissue. The test was designed and validated by Namida Lab, Inc., a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified lab.
Gender:
Female
Ages:
Between 18 years and 100 years
Trial Updated:
12/07/2023
Locations: Namida Lab, Fayetteville, Arkansas
Conditions: Breast Cancer Screening
Register for Updates
Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis
NCT06074315
Recruiting
This is a Pre-IDE, prospective, multicenter, randomized, parallel-group, double-blind, vehicle- controlled study to evaluate safety and effectiveness of Nail Genesis DLSO Product for the treatment of DLSO compared with vehicle in infected great toenails in a total of 338 males and non-pregnant, non-lactating, females between 18 and 65 years of age (inclusive). Subjects will be randomized in a 2:1 ratio to receive either Nail Genesis DLSO Product or vehicle. Subject eligibility will be determine... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
12/06/2023
Locations: Clinical Trials Institute of Northwest Arkansas, Fayetteville, Arkansas
Conditions: Distal Lateral Subungual Onychomycosis, Onychomycosis
Register for Updates
First In Human Study With ABBV-CLS-579 When Given Alone and In Combination In Participants With Locally Advanced Or Metastatic Tumors
NCT04417465
Recruiting
The purpose of this study is to see how safe and effective ABBV-CLS-579 is when used alone and in combination with a PD-1 target agent or with a VEGF TKI. ABBV-CLS-579 is an investigational drug being developed for the treatment of tumors. The trial aims to establish a safe, tolerable, and efficacious dose of ABBV-CLS-579 as monotherapy and in combination. The study will be conducted in three parts. Part 1 Monotherapy Dose Escalation, Part 2 Combination Dose Escalation, and Part 3 Combination... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Highlands Oncology Group Springdale, Springdale, Arkansas
Conditions: Advanced Solid Tumors Cancer
Register for Updates
In Vivo Real-time Detection of Circulating Melanoma Cells
NCT01776905
Recruiting
The objective of this clinical trial is to determine whether a Photoacoustic flow cytometry (PAFC)-based prototype device can detect circulating tumor cells (CTCs) in the blood of melanoma patients in vivo, in real time, and do so at detection limits at least one order of magnitude below the detection limits of currently existing ex vivo methods.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
12/04/2023
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Melanoma
Register for Updates
CapTemY90 for Grade 2 NET Liver Metastases
NCT04339036
Recruiting
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: CARTI Cancer Center, Little Rock, Arkansas
Conditions: Neuroendocrine Tumor Grade 2, Neuroendocrine Tumors
Register for Updates
Stroke Thrombectomy and Aneurysm Registry
NCT04994756
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
All
Ages:
Between 1 year and 120 years
Trial Updated:
11/30/2023
Locations: Washington Regional Medical Center, Fayetteville, Arkansas
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: Arkansas Gastroenterology, North Little Rock, Arkansas
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates
Casting vs Bracing for Idiopathic Early-Onset Scoliosis
NCT04500041
Recruiting
Comparison of casting and bracing for the treatment of idiopathic early onset scoliosis
Gender:
All
Ages:
Between 12 months and 36 months
Trial Updated:
11/27/2023
Locations: Arkansas Children's Hospital, Little Rock, Arkansas
Conditions: Scoliosis Idiopathic, Early-Onset Scoliosis Deformity of Spine
Register for Updates
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022
Recruiting
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose (RP2D) of HQP1351 in subjects with CML chronic phase (CP), accelerated phase (AP), or blast phase (BP) or with Ph+ ALL, who have experienced resistance or intolerance to at least two tyrosine kinase inhibitors (TKIs) or in subjects with Ph+ B-cell precursor (BCP) ALL or lymphoid blast phase CML (CML LBP), who have experienced resistance or intolera... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Highlands Oncology, Rogers, Arkansas
Conditions: Leukemia, Myeloid, Chronic, Myeloid Leukemia, Chronic Myeloid Leukemia, Philadelphia Positive Acute Lymphoblastic Leukemia, B Cell Precursor Type Acute Leukemia
Register for Updates
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
NCT03516279
Recruiting
This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzyme... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Mercy Hospital Fort Smith, Fort Smith, Arkansas
Conditions: Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Minimal Residual Disease
Register for Updates
CHaractErizing CFTR Modulated Changes in Sweat Chloride and Their Association With Clinical Outcomes
NCT03350828
Recruiting
This is a multicenter, cross-sectional, cohort study which will collect contemporary sweat chloride (SC) values from approximately 5000 Cystic Fibrosis (CF) patients prescribed and currently receiving commercially approved Cystic Fibrosis transmembrane conductance regulator (CFTR) modulator therapies.
Gender:
All
Ages:
4 months and above
Trial Updated:
11/21/2023
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Cystic Fibrosis
Register for Updates
SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
NCT04647227
Recruiting
Phase IV multi-center, US-centric, open-label, safety study enrolling participants with Hemophilia A or B with inhibitors12 years of age and older, who are either on long term prophylactic treatment (e.g., emicizumab) at risk of experiencing a breakthrough bleeding event (BE), or who are not on prophylactic treatment who may need to control a BE.
Gender:
All
Ages:
Between 12 years and 100 years
Trial Updated:
11/20/2023
Locations: Arkansas Center for Bleeding Disorders, Little Rock, Arkansas
Conditions: Hemophilia A With Inhibitor, Hemophilia B With Inhibitor
Register for Updates